ClinicalTrials.gg
CompletedNCT02725268Updated Nov 24, 2021Results posted

A Study of Sapanisertib, Combination of Sapanisertib With MLN1117, Paclitaxel and Combination of Sapanisertib With Paclitaxel in Women With Endometrial Cancer

A Phase 2 interventional study of Paclitaxel and Sapanisertib in Endometrial Neoplasms, sponsored by Millennium Pharmaceuticals, Inc.. Completed at 78 sites in 10 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-11-24.

Sponsored by Millennium Pharmaceuticals, Inc. (part of Takeda) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
241
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 39 studies testing paclitaxel in Endometrial Neoplasms — 8 open to participants now, 14 under way, 3 of them phase 3. Paclitaxel · Endometrial Neoplasms.

Enrollment
6th of 34
241 · median 42
Started
2016
with 2 others
Phase 2
26 of 39
5 open now
Registered
22nd of 39
by date

Among the 39 studies testing paclitaxel in Endometrial Neoplasms, this one is the 6th largest by enrollment of the 34 interventional ones that give a count, is one of 3 that started in 2016, is one of 26 in phase 2, and was the 22nd registered.

Endometrial Neoplasms

1,428 studies on the registry are indexed under Endometrial Neoplasms; 472 are open to participants now.

Browse Endometrial Neoplasms studies →

Open to participants now

8 of the 39 studies testing paclitaxel in Endometrial Neoplasms are open now, in 3 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About paclitaxel

Paclitaxel: first FDA approval 1992 (TAXOL), first EMA approval 1999. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 356 Endometrial Neoplasms studies recruiting now, 266 (75%) set no upper age limit and 54 (15%) stop at 75 or younger; 26 take children under 18; 23 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 39 studies testing paclitaxel in Endometrial Neoplasms, or all of them as a file.
02

Study summary

The primary purpose of this study is to determine if sapanisertib in combination with weekly paclitaxel improves progression-free survival (PFS) compared to weekly paclitaxel alone.

Read the detailed description

The drugs being evaluated in this study are sapanisertib and MLN1117. Sapanisertib is being evaluated as a single agent and in combination with paclitaxel or MLN1117 to treat women with advanced, recurrent, or persistent endometrial cancer. This study will evaluate the efficacy and safety of each drug or drug combination.

The study will enroll approximately 241 participants. Participants will be randomly assigned (by chance, like flipping a coin) to one of 4 treatment groups:

  • Paclitaxel 80 mg/m\^2
  • Paclitaxel 80 mg/m\^2 + Sapanisertib 4 mg
  • Sapanisertib 30 mg
  • Sapanisertib 4 mg + MLN1117 200 mg

Participants will receive either paclitaxel intravenous (IV) weekly, Paclitaxel IV along with sapanisertib orally, sapanisertib orally, or sapanisertib and MLN1117 orally.

This is a multicenter, multinational trial. Participants will make multiple visits to the clinic, with an end of treatment visit (EOT) which will occur 30 to 40 days after receiving their last dose of study drug or before the start of any subsequent anticancer therapy. After EOT, participants will be followed for PFS and overall survival (OS).

03

Conditions studied

  • Endometrial Neoplasms

Keywords

  • Drug Therapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Histologic or cytologic diagnosis of endometrial carcinoma (including endometrioid, serous, mixed adenocarcinoma, clear-cell carcinoma, or carcinosarcoma).
  2. Evidence that the endometrial cancer is advanced, recurrent, or persistent and has or is refractory to curative therapy or established treatments.
  3. At least 1 prior platinum-based chemotherapeutic regimen, but not more than 2 prior chemotherapeutic regimens, for management of endometrial carcinoma. Prior treatment may include chemotherapy, chemotherapy/radiation therapy, and/or consolidation/maintenance therapy. Chemotherapy administered in conjunction with primary radiation as a radio-sensitized therapy will be considered a systemic chemotherapy regimen.
  4. by (RECIST) 1.1, defined as at least 1 lesion that can be accurately measured in at least 1 dimension (longest diameter to be recorded). Each lesion must be greater than or equal to (>=) 10 millimeter (mm) in long axis when measured by computed tomography (CT), magnetic resonance imaging (MRI), or caliper measurement by clinical exam. Lymph nodes must be >= 15 mm in short axis when measured by CT or MRI.
  5. Tumor accessible and participant consents to undergo fresh tumor .
  6. Female participants 18 years or older.
  7. (ECOG) performance status of 0 to 2
  8. Female participants who:

    • Are for at least 1 year before the screening visit, OR
    • Are surgically sterile, OR
    • If they are of , agree to practice 1 highly effective method of and 1 additional effective (barrier) method at the same time, from the time of signing the through 90 days (or longer, as mandated by local labeling [example, United States Prescribing Information (USPI), Summary of Product Characteristics (SmPC), etc.]) after the last dose of study drug, OR
    • Agree to practice true abstinence, when this is in line with the preferred and usual lifestyle of the participant. (Periodic abstinence [example, calendar, ovulation, symptothermal, postovulation methods], withdrawal, spermicides only, and lactational amenorrhea are not acceptable methods of contraception. Female and male condoms should not be used together.)
  9. Clinical laboratory values as specified below within 4 weeks before the first dose of study drug:

    • Bone marrow reserve consistent with (ANC) >= 1500 per micro liter (/mcL); count >= 100,000/mcL; (HbA1c) less than (\<) 6.5 percent (%).
    • Total must be less than or equal to (\<=) 1.5 * the (ULN).
    • (ALT) or aspartate aminotransferase (AST) must be \<= 2.5 * the upper limit of the normal range. AST and ALT may be elevated up to 5 times the ULN if their elevation can be reasonably ascribed to the presence of disease in liver.
    • >= 50 milliliter per minute per 1.73 square meter (mL/min/1.73 m\^2) based either on Cockcroft-Gault estimate or based on a 12- or 24-hour urine collection.
    • Fasting serum glucose \< 130 milligram per deciliter (mg/dL) and fasting triglycerides \<= 300 mg/dL.
  10. Ability to swallow oral medications, willingness to perform mucositis prophylaxis, and suitable venous access for the study-required blood sampling.
  11. Voluntary written consent must be given before performance of any study-related procedure not part of standard medical care, with the understanding that consent may be withdrawn by the participant at any time without prejudice to future medical care.

Exclusion criteria

Exclusion Criteria:

  1. Positive serum pregnancy test during the screening period or a positive urine pregnancy test on Day 1 before first dose of study drug. Women who are lactating and breastfeeding are not eligible.
  2. Previous treatment with any weekly taxane regimen.
  3. History of severe reactions to paclitaxel or any of its .
  4. Previous treatment with phosphoinositide 3-kinase (PI3K), serine/threonine-specific protein kinase (AKT), dual PI3K/ mammalian (or mechanistic) target of rapamycin (mTOR) inhibitors, target of rapamycin complex 1/2 (TORC1/2) inhibitors or TORC1 inhibitors.
  5. Initiation of treatment with hematopoietic growth factors, transfusions of blood and blood products, or systemic (either intravenous [IV] or oral steroids, excluding inhalers) within 1 week before administration of the first dose of study drug (participants already receiving erythropoietin on a chronic basis for >=4 weeks are eligible).
  6. Participants who are taking proton pump inhibitors (PPIs) within 7 days of the first dose of study drug or who require treatment with PPIs throughout the trial or those who are taking H2 receptor antagonists within 24 hours of the first dose of study drug.
  7. A (PT) or activated partial thromboplastin time (aPTT) above the or a history of a coagulopathy or bleeding disorder.
  8. Known surface antigen-positive, or known or suspected active infection.
  9. Sensory or motor neuropathy >= Grade 2.
  10. Central nervous system (CNS) , endometrial leiomyosarcoma, or endometrial stromal sarcoma.
  11. Manifestations of malabsorption due to prior gastrointestinal surgery, gastrointestinal disease, or for some other reason that may alter the absorption of sapanisertib or MLN1117. In addition, participants with enteric stomata are also excluded.
  12. Other co-morbidities, such as uncontrolled pulmonary disease, active CNS disease, active infection, or any other condition that could compromise participation of the participant in the study.
  13. Known infection.
  14. History of any of the following within the last 6 months before administration of the first dose of study drug:

    • Ischemic myocardial event, including angina requiring therapy and artery revascularization procedures.
    • Ischemic cerebrovascular event, including and artery revascularization procedures.
    • Requirement for inotropic support (excluding digoxin) or serious (uncontrolled) cardiac arrhythmia (including atrial flutter/fibrillation, ventricular fibrillation, or ventricular tachycardia).
    • Placement of a pacemaker for control of rhythm.
    • Class III or IV heart failure.
    • Pulmonary embolism.
  15. Significant active cardiovascular or pulmonary disease before administration of the first dose of study drug, including:

    • Uncontrolled hypertension (that is, either systolic blood pressure > 180 millimeter of mercury [mm Hg] or diastolic blood pressure > 95 mm Hg).
    • Pulmonary hypertension.
    • Uncontrolled asthma or oxygen saturation \< 90% by arterial blood gas analysis or pulse oximetry on room air.
    • Significant valvular disease; severe regurgitation or stenosis by imaging independent of symptom control with medical intervention; or history of valve replacement.
    • Medically significant (symptomatic) bradycardia.
    • History of arrhythmia requiring an implantable cardiac defibrillator.
    • Baseline prolongation of the rate- interval (QTc; example, repeated demonstration of QTc interval > 480 millisecond [ms], or history of congenital long QT syndrome, or torsades de pointes).
  16. Diagnosed or treated for another within 2 years before administration of the first dose of study drug or previously diagnosed with another malignancy and have any evidence of residual disease. Participants with non-melanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resection.
  17. Participants with endometrioid histology and confirmed expression of estrogen receptors (ER) and/or progesterone receptors (PgR) who have not received prior endocrine therapy and for whom endocrine therapy is currently indicated.
Terms in these criteria, in plain language(30)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
241 participants (actual)

Study arms

  • Experimental
    Paclitaxel 80 mg/m^2

    Paclitaxel 80 milligrams per square meter (mg/m\^2), IV, weekly on Days 1, 8, and 15 of a 28-day cycle until disease progression, unacceptable toxicity, or withdraw consent (the median exposure was up to approximately 13 weeks).

    Drug: Paclitaxel

  • Experimental
    Paclitaxel 80 mg/m^2 + Sapanisertib 4 mg

    Paclitaxel 80 mg/m\^2, IV, weekly on Days 1, 8, and 15 of a 28-day cycle along with sapanisertib 4 milligrams (mg), capsule, orally on Days 2-4, 9-11, 16-18, and 23-25 of a 28-day cycle until disease progression, unacceptable toxicity, or withdraw consent (the median exposure was up to approximately 20 weeks).

    Drug: Paclitaxel · Drug: Sapanisertib

  • Experimental
    Sapanisertib 30 mg

    Sapanisertib 30 mg, capsule, orally, once weekly on Days 1, 8, 15, and 22 of a 28-day cycle until disease progression, unacceptable toxicity, or withdraw consent (the median exposure was up to approximately 6 weeks).

    Drug: Sapanisertib

  • Experimental
    Sapanisertib 4 mg + MLN1117 200 mg

    Sapanisertib 4 mg, capsule, orally and MLN1117 200 mg, capsule, orally on Days 1-3, 8-10, 15-17, and 22-24 of a 28-day cycle until disease progression, unacceptable toxicity, or withdraw consent (the median exposure was up to approximately 8 weeks).

    Drug: Sapanisertib · Drug: MLN1117

Interventions

  • Paclitaxel intravenous solution.

  • Sapanisertib capsules.

    Also known as: MLN0128, INK128, TAK-228

  • MLN1117 capsules.

    Also known as: TAK-117, INK1117

06

What researchers measure

Primary outcomes

  1. Progression Free Survival (PFS)

    PFS is defined as the time in months from the date of randomization to the date of first documentation of progressive disease (PD) or death due to any cause, whichever occurs first. Per RECIST v1.1, PD was defined as at least a 20% increase in the sum of the longest diameter (LD) of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions.

    Time frame: Up to approximately 30 months

Secondary outcomes

  1. Number of Participants Who Experienced at Least One Treatment-emergent Adverse Event (TEAE)

    An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A TEAE is defined as an adverse event with an onset that occurs after receiving study drug.

    Time frame: From the first dose of study drug through 30 days after the last dose of study drug (Up to approximately 54 months)

  2. Overall Survival (OS)

    OS is defined as the time in months from the date of randomization to the date of death.

    Time frame: Up to approximately 54 months

  3. Time to Tumor Progression (TTP)

    TTP is defined as the time in months from the date of randomization to the date of first documentation of progression. Per RECIST 1.1, PD was defined as at least a 20% increase in the sum of the longest diameter (LD) of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions.

    Time frame: Up to 30 months

  4. Overall Response Rate (ORR)

    ORR is defined as the percentage of participants who achieved a best response of a complete response (CR) or partial response (PR). Per RECIST v1.1, CR was defined as disappearance of all target lesions, non-target lesions, no new lesions, and normalization of tumor marker level. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, no progression in non-target lesion, and no new lesions.

    Time frame: Up to 30 months

  5. Clinical Benefit Rate (CBR)

    CBR is defined as the percentage of participants with CR or PR or SD (SD of any duration). Per RECIST v1.1, CR was defined as disappearance of all target lesions, non-target lesions, no new lesions, and normalization of tumor marker level. PR is defined as at least a 30% decrease in the sum of diameters of target lesions, no progression in non-target lesion, and no new lesions. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD. PD was defined as at least a 20% increase in the sum of the longest diameter (LD) of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions.

    Time frame: Up to 30 months

  6. Clinical Benefit Rate (CBR) at Week 16 (CBR-16)

    CBR-16 is defined as the percentage of participants who achieved CR or PR of any duration or have SD with a duration of at least 16 weeks. Per RECIST v1.1, CR was defined as disappearance of all target lesions, non-target lesions, no new lesions, and normalization of tumor marker level. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, no progression in non-target lesion, and no new lesions. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD. PD was defined as at least a 20% increase in the sum of the longest diameter (LD) of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions.

    Time frame: Week 16

07

Results

Posted Jun 9, 2020

Participant flow

Participants took part in the study at 60 investigative sites in Australia, Belgium, Germany, Italy, Netherlands, Norway, Spain, United Kingdom, Canada and the United States from 01 April 2016 to 30 October 2020.

Participant flow — Overall Study
MilestonePaclitaxel 80 mg/m^2Paclitaxel 80 mg/m^2 + Sapanisertib 4 mgSapanisertib 30 mgSapanisertib 4 mg + MLN1117 200 mg
Started90904120
Started90904120
Completed182032
Completed182032
Not completed72703818
Withdrew: Death58593016
Withdrew: Lost to follow-up4301
Withdrew: Site terminated by sponsor0100
Withdrew: Withdrawal by subject8681
Withdrew: Reason not specified2100

Outcome measures

PrimaryProgression Free Survival (PFS)

PFS is defined as the time in months from the date of randomization to the date of first documentation of progressive disease (PD) or death due to any cause, whichever occurs first. Per RECIST v1.1, PD was defined as at least a 20% increase in the sum of the longest diameter (LD) of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions.

Time frame:
Up to approximately 30 months
Reported as:
Median · months
Progression Free Survival (PFS)
monthsPaclitaxel 80 mg/m^2Paclitaxel 80 mg/m^2 + Sapanisertib 4 mgSapanisertib 30 mgSapanisertib 4 mg + MLN1117 200 mg
Progression Free Survival (PFS)3.7 (2.3 to 4.5)5.6 (3.8 to 6.2)2.1 (1.9 to 3.5)2.0 (1.5 to 3.3)
Statistical analysis
  • Paclitaxel 80 mg/m^2 vs Paclitaxel 80 mg/m^2 + Sapanisertib 4 mg · Stratified Log-rank Test · p = =0.178 (The p-value was obtained using stratified log-rank test with histological subtype, lines of prior chemotherapy and prior taxane therapy (original stratification values).) · Hazard ratio (hr): 0.80 · 95% CI 0.58 to 1.12The hazard ratio was obtained using a stratified Cox proportional hazard model adjusted for histological subtype, lines of prior chemotherapy and prior taxane therapy. A hazard ratio of \<1 was considered statistically significant.
  • Paclitaxel 80 mg/m^2 vs Sapanisertib 30 mg · Stratified Log-rank Test · p = =0.092 (The p-value was obtained using stratified log-rank test with histological subtype, lines of prior chemotherapy and prior taxane therapy (original stratification values).) · Hazard ratio (hr): 1.85 · 95% CI 1.19 to 2.86The hazard ratio was obtained using a stratified Cox proportional hazard model adjusted for histological subtype, lines of prior chemotherapy and prior taxane therapy. A hazard ratio of \<1 was considered statistically significant.
  • Paclitaxel 80 mg/m^2 vs Sapanisertib 4 mg + MLN1117 200 mg · Stratified Log-rank Test · p = =0.147 (The p-value was obtained using stratified log-rank test with histological subtype, lines of prior chemotherapy and prior taxane therapy (original stratification values).) · Hazard ratio (hr): 2.57 · 95% CI 1.47 to 4.49The hazard ratio was obtained using a stratified Cox proportional hazard model adjusted for histological subtype, lines of prior chemotherapy and prior taxane therapy. A hazard ratio of \<1 was considered statistically significant.
SecondaryNumber of Participants Who Experienced at Least One Treatment-emergent Adverse Event (TEAE)

An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A TEAE is defined as an adverse event with an onset that occurs after receiving study drug.

Time frame:
From the first dose of study drug through 30 days after the last dose of study drug (Up to approximately 54 months)
Reported as:
Count of participants · Participants
Number of Participants Who Experienced at Least One Treatment-emergent Adverse Event (TEAE)
ParticipantsPaclitaxel 80 mg/m^2Paclitaxel 80 mg/m^2 + Sapanisertib 4 mgSapanisertib 30 mgSapanisertib 4 mg + MLN1117 200 mg
Number of Participants Who Experienced at Least One Treatment-emergent Adverse Event (TEAE)87864120
SecondaryOverall Survival (OS)

OS is defined as the time in months from the date of randomization to the date of death.

Time frame:
Up to approximately 54 months
Reported as:
Median · months
Overall Survival (OS)
monthsPaclitaxel 80 mg/m^2Paclitaxel 80 mg/m^2 + Sapanisertib 4 mgSapanisertib 30 mgSapanisertib 4 mg + MLN1117 200 mg
Overall Survival (OS)12.7 (9.8 to 19.6)13.8 (9.9 to 19.1)12.5 (9.0 to 15.7)11.1 (2.7 to 17.5)
Statistical analysis
  • Paclitaxel 80 mg/m^2 vs Paclitaxel 80 mg/m^2 + Sapanisertib 4 mg · Stratified Log-rank Test · p = =0.968 (The p-value was obtained using stratified log-rank test with histological subtype, lines of prior chemotherapy and prior taxane therapy (original stratification values).) · Hazard ratio (hr): 1.04 · 95% CI 0.72 to 1.50The hazard ratio was obtained using a stratified Cox proportional hazard model adjusted for histological subtype, lines of prior chemotherapy and prior taxane therapy. A hazard ratio of \<1 was considered statistically significant.
  • Paclitaxel 80 mg/m^2 vs Sapanisertib 30 mg · Stratified Log-rank Test · p = =0.145 (The p-value was obtained using stratified log-rank test with histological subtype, lines of prior chemotherapy and prior taxane therapy (original stratification values).) · Hazard ratio (hr): 1.50 · 95% CI 0.95 to 2.37The hazard ratio was obtained using a stratified Cox proportional hazard model adjusted for histological subtype, lines of prior chemotherapy and prior taxane therapy. A hazard ratio of \<1 was considered statistically significant.
  • Paclitaxel 80 mg/m^2 vs Sapanisertib 4 mg + MLN1117 200 mg · Stratified Log-rank Test · p = =0.243 (The p-value was obtained using stratified log-rank test with histological subtype, lines of prior chemotherapy and prior taxane therapy (original stratification values).) · Hazard ratio (hr): 1.54 · 95% CI 0.87 to 2.73The hazard ratio was obtained using a stratified Cox proportional hazard model adjusted for histological subtype, lines of prior chemotherapy and prior taxane therapy. A hazard ratio of \<1 was considered statistically significant.
SecondaryTime to Tumor Progression (TTP)

TTP is defined as the time in months from the date of randomization to the date of first documentation of progression. Per RECIST 1.1, PD was defined as at least a 20% increase in the sum of the longest diameter (LD) of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions.

Time frame:
Up to 30 months
Reported as:
Median · months
Time to Tumor Progression (TTP)
monthsPaclitaxel 80 mg/m^2Paclitaxel 80 mg/m^2 + Sapanisertib 4 mgSapanisertib 30 mgSapanisertib 4 mg + MLN1117 200 mg
Time to Tumor Progression (TTP)3.7 (2.5 to 5.4)5.7 (3.8 to 7.2)2.3 (1.9 to 4.2)2.2 (1.8 to 3.7)
Statistical analysis
  • Paclitaxel 80 mg/m^2 vs Paclitaxel 80 mg/m^2 + Sapanisertib 4 mg · Stratified Log-rank Test · p = =0.170 (The p-value was obtained using stratified log-rank test with histological subtype, lines of prior chemotherapy and prior taxane therapy (original stratification values).) · Hazard ratio (hr): 0.79 · 95% CI 0.57 to 1.11The hazard ratio was obtained using a stratified Cox proportional hazard model adjusted for histological subtype, lines of prior chemotherapy and prior taxane therapy. A hazard ratio of \<1 was considered statistically significant.
  • Paclitaxel 80 mg/m^2 vs Sapanisertib 30 mg · Stratified Log-rank Test · p = =0.224 (The p-value was obtained using stratified log-rank test with histological subtype, lines of prior chemotherapy and prior taxane therapy (original stratification values).) · Hazard ratio (hr): 1.67 · 95% CI 1.04 to 2.68The hazard ratio was obtained using a stratified Cox proportional hazard model adjusted for histological subtype, lines of prior chemotherapy and prior taxane therapy. A hazard ratio of \<1 was considered statistically significant.
  • Paclitaxel 80 mg/m^2 vs Sapanisertib 4 mg + MLN1117 200 mg · Stratified Log-rank Test · p = =0.244 (The p-value was obtained using stratified log-rank test with histological subtype, lines of prior chemotherapy and prior taxane therapy (original stratification values).) · Hazard ratio (hr): 2.28 · 95% CI 1.32 to 3.96The hazard ratio was obtained using a stratified Cox proportional hazard model adjusted for histological subtype, lines of prior chemotherapy and prior taxane therapy. A hazard ratio of \<1 was considered statistically significant.
SecondaryOverall Response Rate (ORR)

ORR is defined as the percentage of participants who achieved a best response of a complete response (CR) or partial response (PR). Per RECIST v1.1, CR was defined as disappearance of all target lesions, non-target lesions, no new lesions, and normalization of tumor marker level. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, no progression in non-target lesion, and no new lesions.

Time frame:
Up to 30 months
Reported as:
Number · percentage of participants
Overall Response Rate (ORR)
percentage of participantsPaclitaxel 80 mg/m^2Paclitaxel 80 mg/m^2 + Sapanisertib 4 mgSapanisertib 30 mgSapanisertib 4 mg + MLN1117 200 mg
Overall Response Rate (ORR)18.424.44.90
Statistical analysis
  • Paclitaxel 80 mg/m^2 vs Paclitaxel 80 mg/m^2 + Sapanisertib 4 mg · Odds ratio (or): 1.39 · 95% CI 0.66 to 2.90The odds ratio and 95% confidence intervals were obtained using a stratified Cochran-Mantel-Haenszel (CMH) model with histological subtype, lines of prior chemotherapy and prior taxane therapy (original stratification values).
  • Paclitaxel 80 mg/m^2 vs Sapanisertib 30 mg · Odds ratio (or): 0.22 · 95% CI 0.04 to 1.14The odds ratio and 95% confidence intervals were obtained using a stratified CMH model with histological subtype, lines of prior chemotherapy and prior taxane therapy (original stratification values).
  • Paclitaxel 80 mg/m^2 vs Sapanisertib 4 mg + MLN1117 200 mg · Odds ratio (or): 0.00 · 95% CI 0.00 to 0.00The odds ratio and 95% confidence intervals were obtained using a stratified CMH model with histological subtype, lines of prior chemotherapy and prior taxane therapy (original stratification values).
SecondaryClinical Benefit Rate (CBR)

CBR is defined as the percentage of participants with CR or PR or SD (SD of any duration). Per RECIST v1.1, CR was defined as disappearance of all target lesions, non-target lesions, no new lesions, and normalization of tumor marker level. PR is defined as at least a 30% decrease in the sum of diameters of target lesions, no progression in non-target lesion, and no new lesions. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD. PD was defined as at least a 20% increase in the sum of the longest diameter (LD) of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions.

Time frame:
Up to 30 months
Reported as:
Number · percentage of participants
Clinical Benefit Rate (CBR)
percentage of participantsPaclitaxel 80 mg/m^2Paclitaxel 80 mg/m^2 + Sapanisertib 4 mgSapanisertib 30 mgSapanisertib 4 mg + MLN1117 200 mg
Clinical Benefit Rate (CBR)57.580.234.135.0
Statistical analysis
  • Paclitaxel 80 mg/m^2 vs Paclitaxel 80 mg/m^2 + Sapanisertib 4 mg · Odds ratio (or): 3.02 · 95% CI 1.53 to 5.96The odds ratio and 95% confidence intervals were obtained using a stratified CMH model with histological subtype, lines of prior chemotherapy and prior taxane therapy (original stratification values).
  • Paclitaxel 80 mg/m^2 vs Sapanisertib 30 mg · Odds ratio (or): 0.40 · 95% CI 0.18 to 0.86The odds ratio and 95% confidence intervals were obtained using a stratified CMH model with histological subtype, lines of prior chemotherapy and prior taxane therapy (original stratification values).
  • Paclitaxel 80 mg/m^2 vs Sapanisertib 4 mg + MLN1117 200 mg · Odds ratio (or): 0.43 · 95% CI 0.15 to 1.21The odds ratio and 95% confidence intervals were obtained using a stratified CMH model with histological subtype, lines of prior chemotherapy and prior taxane therapy (original stratification values).
SecondaryClinical Benefit Rate (CBR) at Week 16 (CBR-16)

CBR-16 is defined as the percentage of participants who achieved CR or PR of any duration or have SD with a duration of at least 16 weeks. Per RECIST v1.1, CR was defined as disappearance of all target lesions, non-target lesions, no new lesions, and normalization of tumor marker level. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, no progression in non-target lesion, and no new lesions. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD. PD was defined as at least a 20% increase in the sum of the longest diameter (LD) of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Clinical Benefit Rate (CBR) at Week 16 (CBR-16)
percentage of participantsPaclitaxel 80 mg/m^2Paclitaxel 80 mg/m^2 + Sapanisertib 4 mgSapanisertib 30 mgSapanisertib 4 mg + MLN1117 200 mg
Clinical Benefit Rate (CBR) at Week 16 (CBR-16)36.851.217.15.0
Statistical analysis
  • Paclitaxel 80 mg/m^2 vs Paclitaxel 80 mg/m^2 + Sapanisertib 4 mg · Odds ratio (or): 2.62 · 95% CI 0.89 to 7.67The odds ratio and 95% confidence intervals were obtained using a stratified CMH model with histological subtype, lines of prior chemotherapy and prior taxane therapy (original stratification values).
  • Paclitaxel 80 mg/m^2 vs Sapanisertib 30 mg · Odds ratio (or): 0.15 · 95% CI 0.05 to 0.51The odds ratio and 95% confidence intervals were obtained using a stratified CMH model with histological subtype, lines of prior chemotherapy and prior taxane therapy (original stratification values).
  • Paclitaxel 80 mg/m^2 vs Sapanisertib 4 mg + MLN1117 200 mg · Odds ratio (or): 0.07 · 95% CI 0.01 to 0.67The odds ratio and 95% confidence intervals were obtained using a stratified CMH model with histological subtype, lines of prior chemotherapy and prior taxane therapy (original stratification values).

Adverse events

Collected over Up to the end of study (approximately up to 54 months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Paclitaxel 80 mg/m^258/90 (64.4%)23/87 (26.4%)85/87 (97.7%)
Paclitaxel 80 mg/m^2 + Sapanisertib 4 mg59/90 (65.6%)47/86 (54.7%)86/86 (100%)
Sapanisertib 30 mg30/41 (73.2%)14/41 (34.1%)41/41 (100%)
Sapanisertib 4 mg + MLN1117 200 mg16/20 (80%)7/20 (35%)20/20 (100%)
Most frequent serious events
Showing 10 of 90
Most frequent serious events
EventPaclitaxel 80 mg/m^2Paclitaxel 80 mg/m^2 + Sapanisertib 4 mgSapanisertib 30 mgSapanisertib 4 mg + MLN1117 200 mg
NauseaGastrointestinal disorders0/872/862/412/20
VomitingGastrointestinal disorders0/872/862/412/20
General physical health deteriorationGeneral disorders3/873/861/411/20
FatigueGeneral disorders0/872/861/411/20
GastroenteritisInfections and infestations0/870/860/411/20
Blood glucose increasedInvestigations0/870/860/411/20
Transaminases increasedInvestigations0/870/860/411/20
Endometrial cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/870/860/411/20
Glucose tolerance impairedMetabolism and nutrition disorders0/870/860/411/20
SepsisInfections and infestations1/873/860/410/20
Most frequent other events
Showing 10 of 82
Most frequent other events
EventPaclitaxel 80 mg/m^2Paclitaxel 80 mg/m^2 + Sapanisertib 4 mgSapanisertib 30 mgSapanisertib 4 mg + MLN1117 200 mg
NauseaGastrointestinal disorders29/8753/8630/4116/20
VomitingGastrointestinal disorders20/8724/8631/4115/20
DiarrhoeaGastrointestinal disorders31/8748/8615/4113/20
AnaemiaBlood and lymphatic system disorders32/8748/865/416/20
AstheniaGeneral disorders7/8726/869/4110/20
Decreased appetiteMetabolism and nutrition disorders16/8733/8620/418/20
FatigueGeneral disorders39/8740/8618/417/20
HyperglycaemiaMetabolism and nutrition disorders8/8717/8615/415/20
AlopeciaSkin and subcutaneous tissue disorders31/8727/861/410/20
ConstipationGastrointestinal disorders25/8720/8614/415/20

Baseline characteristics

Intent-to-treat (ITT) population included all randomized participants.

Age, Continuous
Age, Continuous(years)Paclitaxel 80 mg/m^2Paclitaxel 80 mg/m^2 + Sapanisertib 4 mgSapanisertib 30 mgSapanisertib 4 mg + MLN1117 200 mgTotal
Mean63.7 ± 7.1464.4 ± 7.6364.0 ± 6.9962.0 ± 10.2063.9 ± 7.57
Sex: Female, Male
Sex: Female, Male(Participants)Paclitaxel 80 mg/m^2Paclitaxel 80 mg/m^2 + Sapanisertib 4 mgSapanisertib 30 mgSapanisertib 4 mg + MLN1117 200 mgTotal
Female90904120241
Male00000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Paclitaxel 80 mg/m^2Paclitaxel 80 mg/m^2 + Sapanisertib 4 mgSapanisertib 30 mgSapanisertib 4 mg + MLN1117 200 mgTotal
Hispanic or Latino353415
Not Hispanic or Latino84803715216
Unknown or Not Reported351110
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Paclitaxel 80 mg/m^2Paclitaxel 80 mg/m^2 + Sapanisertib 4 mgSapanisertib 30 mgSapanisertib 4 mg + MLN1117 200 mgTotal
White77783718210
Black or African American34018
Native Hawaiian or other Pacific Islander10102
Asian631111
Other02204
Not Reported33006
Region of Enrollment
Region of Enrollment(Participants)Paclitaxel 80 mg/m^2Paclitaxel 80 mg/m^2 + Sapanisertib 4 mgSapanisertib 30 mgSapanisertib 4 mg + MLN1117 200 mgTotal
Australia563216
Belgium5102320
Germany641011
Italy14229449
Netherlands23005
Norway31105
Spain1075628
United Kingdom946221
Canada15102027
United States212312359
Height
Height(cm)Paclitaxel 80 mg/m^2Paclitaxel 80 mg/m^2 + Sapanisertib 4 mgSapanisertib 30 mgSapanisertib 4 mg + MLN1117 200 mgTotal
Mean160.60 ± 6.335160.23 ± 5.798159.01 ± 6.471162.67 ± 5.854160.36 ± 6.16
Weight
Weight(kg)Paclitaxel 80 mg/m^2Paclitaxel 80 mg/m^2 + Sapanisertib 4 mgSapanisertib 30 mgSapanisertib 4 mg + MLN1117 200 mgTotal
Mean73.29 ± 18.78372.13 ± 18.43375.35 ± 17.96971.81 ± 18.61373.11 ± 18.418
08

Study locations

78 sites
  • University of Alabama Comprehensive Cancer Center
    Birmingham, Alabama 35294-3300, United States
  • University of Arizona Cancer Center
    Phoenix, Arizona 85013, United States
  • Marin Cancer Care
    Greenbrae, California 94904, United States
  • University of California San Diego Medical Center
    La Jolla, California 92093-1503, United States
  • University of California at San Francisco (PARENT)
    San Francisco, California 94115, United States
  • Stanford School of Medicine
    Stanford, California 94305, United States
  • H. Lee Moffitt Cancer Center and Research Institute, Inc
    Tampa, Florida 33612-9416, United States
  • Florida Cancer Specialists
    West Palm Beach, Florida 33401, United States
  • Augusta University
    Augusta, Georgia 30912, United States
  • Franciscan St. Francis Health
    Indianapolis, Indiana 46237, United States
  • University of Kansas Medical Center Research Institute, Inc.
    Westwood, Kansas 66205, United States
  • Massachusetts General Hospital Cancer Center
    Boston, Massachusetts 02114, United States
  • Washington University
    Saint Louis, Missouri 63108, United States
  • NYU Langone Medical Center Clinic
    New York, New York 10016, United States
  • Memorial Sloan Kettering Cancer Center
    New York, New York 10065-6094, United States
  • Levine Cancer Institute
    Charlotte, North Carolina 28204, United States
  • Oklahoma University Health Sciences Center
    Oklahoma City, Oklahoma 73104, United States
  • Fox Chase Cancer Center
    Philadelphia, Pennsylvania 19111, United States
  • University of Pittsburgh Medical Center Cancer Center at Magee-Womens Hospital
    Pittsburgh, Pennsylvania 15232, United States
  • Sarah Cannon Research Institute
    Nashville, Tennessee 37203, United States
  • University of Texas Southwestern Medical Center
    Dallas, Texas 75390, United States
  • St George Hospital
    Kogarah, New South Wales 2217, Australia
  • Westmead Hospital
    Westmead, New South Wales 2145, Australia
  • Royal Brisbane and Women's Hospital
    Herston, Queensland 4029, Australia
  • Monash Medical Centre Clayton
    Clayton, Victoria 3168, Australia
  • Sunshine Hospital
    Footscray, Victoria 3011, Australia
  • Cabrini Hospital Malvern
    Malvern, Victoria 3144, Australia
  • Peter MacCallum Cancer Centre-East Melbourne
    Melbourne, Victoria 3000, Australia
  • UZ Antwerpen
    Edegem, Antwerpen 2650, Belgium
  • Cliniques Universitaires Saint-Luc
    Bruxelles, 1200, Belgium
  • UZ Leuven
    Leuven, 3000, Belgium
  • Centre Hospitalier Universitaire de Liege Site Sart Tilman
    Liege, 4000, Belgium
  • GasthuisZusters Antwerpen Sint-Augustinus
    Wilrijk, 2610, Belgium
  • Tom Baker Cancer Centre
    Calgary, Alberta T2N 4N2, Canada
  • Juravinski Cancer Clinic
    Hamilton, Ontario L8V 5C2, Canada
  • LHSC - Victoria Hospital
    London, Ontario N6A 4L6, Canada
  • Ottawa Hospital Cancer Centre
    Ottawa, Ontario K1H 8L6, Canada
  • University Health Network - Princess Margaret Cancer Centre
    Toronto, Ontario M5G 2M9, Canada
  • CHUM Hopital Notre-Dame
    Montreal, Quebec H2X 3E4, Canada
  • Universitaetsmedizin Greifswald
    Greifswald, Mecklenburg Vorpommern 17489, Germany
  • Medizinische Hochschule Hannover
    Hannover, Niedersachsen 30625, Germany
  • Universitaetsklinikum Carl Gustav Carus TU Dresden
    Dresden, Sachsen 01307, Germany
  • Universitaetsklinikum Schleswig-Holstein - Campus Luebeck
    Luebeck, Schleswig Holstein 23538, Germany
  • Charite - Universitaetsmedizin Berlin - Campus Virchow-Klinikum
    Berlin, 13353, Germany
  • Istituto Scientifico Romagnolo Per Lo Studio e La Cura Dei Tumori
    Meldola, Forli - Cesena 47014, Italy
  • Spedali Civili di Brescia
    Brescia, 25123, Italy
  • Ente Ospedaliero Ospedali Galliera
    Genova, 16128, Italy
  • Fondazione IRCCS Istituto Nazionale dei Tumori
    Milano, 20133, Italy
  • IEO Istituto Europeo di Oncologia
    Milano, 20141, Italy
  • Istituto Tumori Napoli Fondazione G. Pascale
    Napoli, 80131, Italy
  • Azienda Unita Sanitaria Locale di Ravenna
    Ravenna, 48121, Italy
  • Istituto Nationale Tumori Regina Elena
    Roma, 00144, Italy
  • Universita degli Studi di Roma "La Sapienza" - Umberto I Policlinico di Roma
    Roma, 00161, Italy
  • Fondazione Policlinico Universitario Agostino Gemelli
    Roma, 00168, Italy
  • Maastricht Universitair Medisch Centrum
    Maastricht, Limburg 6229 HX, Netherlands
  • Academisch Medisch Centrum
    Amsterdam, Noord-holland 1105 AZ, Netherlands
  • Erasmus Medisch Centrum Daniel den Hoed
    Rotterdam, Zuid-holland 3015 GD, Netherlands
  • Universitair Medisch Centrum Groningen
    Groningen, 9700 RB, Netherlands
  • Universitair Medisch Centrum Utrecht
    Utrecht, 3584 CX, Netherlands
  • Haukeland universitetssykehus, Kvinneklinikken
    Bergen, 5021, Norway
  • Radiumhospitalet
    Oslo, 0310, Norway
  • Stavanger University Hospital
    Stavanger, 4011, Norway
  • Hospital Universitari Vall d'Hebron
    Barcelona, 08035, Spain
  • MD Anderson Cancer Centre
    Madrid, 28033, Spain
  • Hospital Universitario Ramon y Cajal
    Madrid, 28034, Spain
  • Hospital Universitario Clinico San Carlos
    Madrid, 28040, Spain
  • Hospital Universitario La Paz
    Madrid, 28046, Spain
  • Centro Integral Oncologico Clara Campal
    Madrid, 28050, Spain
  • Instituto Valenciano de Oncologia IVO
    Valencia, 46009, Spain
  • Bristol Haematology and Oncology Centre
    Bristol, Avon BS2 8ED, United Kingdom
  • Royal Devon and Exeter Hospital (Wonford)
    Exeter, Devon EX2 5DW, United Kingdom
  • University College London Hospitals
    London, Greater London NW1 2BU, United Kingdom
  • Royal Marsden Hospital
    London, Greater London SW3 6JJ, United Kingdom
  • Hammersmith Hospital
    London, Greater London W12 0HS, United Kingdom
  • The Christie
    Manchester, Greater Manchester M20 4BX, United Kingdom
  • Royal Marsden Hospital
    Sutton, Surrey SM2 5PT, United Kingdom
  • University Hospital Coventry
    Coventry, CV2 2DX, United Kingdom
  • Beatson West of Scotland Cancer Centre
    Glasgow, G12 0YN, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Takeda makes patient-level, de-identified data sets and associated documents available for all interventional studies after applicable marketing approvals and commercial availability have been received (or program is completely terminated), an opportunity for the primary publication of the research and final report development has been allowed, and other criteria have been met as set forth in Takeda's Data Sharing Policy (see www.TakedaClinicalTrials.com for details). To obtain access, researchers must submit a legitimate academic research proposal for adjudication by an independent review panel, who will review the scientific merit of the research and the requestor's qualifications and conflict of interest that can result in potential bias. Once approved, qualified researchers who sign a data sharing agreement are provided access to these data in a secure research environment.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2016 to primary completion in Jul 2019, 39 months.

Results were first posted in Jun 2020, 11 months after primary completion.

Of 139 phase 2 interventional studies under Endometrial Neoplasms, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 115. This study's 39 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 28, 2016
First posted
Mar 31, 2016
StartActual
Apr 1, 2016
Primary completionActual
Jul 2, 2019
CompletionActual
Oct 30, 2020
Results first posted
Jun 9, 2020
Last update
Nov 24, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 24, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02725268
Collaborators
European Network of Translational Research in Ovarian Cancer - EUTROC, European Network of Individualized Treatment in Endometrial Cancer - ENITEC
Responsible party
Sponsor
First posted
Mar 31, 2016
Start date
Apr 1, 2016
Primary completion
Jul 2, 2019
Completion
Oct 30, 2020
Results posted
Jun 9, 2020
Last update
Nov 24, 2021

Study contacts

Medical Director Clinical Science
study director · Millennium Pharmaceuticals, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Paclitaxel · Sapanisertib · Serabelisib

Start the discussion